Skip to main content
Fig. 1 | Journal of Nanobiotechnology

Fig. 1

From: Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer

Fig. 1

Dual blockade of LAG3 and TIGIT improves treatment outcome of NBTXR3-mediated immunoradiotherapy. A Treatment scheme. 129/SvEv syngeneic female mice (8–12 weeks old) were inoculated with 344SQR cells on the right leg and left leg to establish primary and secondary tumors, respectively. The primary tumors were intratumorally injected with NBTXR3 on day 7, followed by three fractions of 12 Gy radiation on days 8, 9, and 10. αPD1 (200 µg), αLAG3 (200 µg), and αTIGIT (200 µg) were administered at the indicated time points via intraperitoneal injection. The tumor size was monitored, and the mice were euthanized when the tumor dimension reached 14 mm. B Tumor volume of the mice (n = 8) receiving the indicated treatment and survival curve. C Tumor volume and survival rate of the mice (n = 8) for comparing the efficacy of αLAG3, αTIGIT, and their combination when added to NBTXR3 + XRT + αPD1. Tumor volumes were compared by two-way analysis of variance and were expressed as mean tumor volume ± standard error of the mean ± SEM. Mouse survival rates were analyzed with the Kaplan–Meier method. P < 0.05 was considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, NS, not significant

Back to article page